Loading...
XTAI3164
Market cap51mUSD
Dec 23, Last price  
19.60TWD
1D
0.51%
1Q
-14.41%
Jan 2017
-16.60%
Name

GenMont Biotech Inc

Chart & Performance

D1W1MN
XTAI:3164 chart
P/E
51.40
P/S
5.33
EPS
0.38
Div Yield, %
3.57%
Shrs. gr., 5y
-0.64%
Rev. gr., 5y
-4.79%
Revenues
318m
-13.71%
352,848,000514,577,000286,214,000226,821,000308,937,000564,525,000534,719,000540,780,000552,941,000406,532,000346,244,000325,191,000427,929,000368,546,000318,015,000
Net income
33m
-42.10%
86,234,000147,542,00038,159,00028,890,00030,891,000-386,158,000-98,028,000-235,938,00045,600,000158,019,00057,451,00060,884,000113,132,00056,978,00032,991,000
CFO
35m
-74.92%
108,533,000200,034,00039,937,000-25,239,000100,371,000-61,996,000-5,010,00045,337,00077,559,00056,032,00074,515,000118,273,000111,658,000137,948,00034,599,000
Dividend
Jun 17, 20240.5 TWD/sh
Earnings
May 29, 2025

Profile

GenMont Biotech Incorporation engages in the research, development, production, and sale of functional probiotic products in Taiwan. The company also offers probiotics with special functions; and original formula design and manufacturing, and equipment manufacturing services on health care food, as well as cooperates in the research, production, and clinical trial of various products. GenMont Biotech Incorporation was founded in 2000 and is headquartered in Tainan City, Taiwan.
IPO date
Jun 12, 2003
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
318,015
-13.71%
368,546
-13.88%
427,929
31.59%
Cost of revenue
310,290
308,364
299,592
Unusual Expense (Income)
NOPBT
7,725
60,182
128,337
NOPBT Margin
2.43%
16.33%
29.99%
Operating Taxes
5,732
18,797
29,823
Tax Rate
74.20%
31.23%
23.24%
NOPAT
1,993
41,385
98,514
Net income
32,991
-42.10%
56,978
-49.64%
113,132
85.82%
Dividends
(60,460)
(95,008)
(49,215)
Dividend yield
2.83%
4.63%
2.33%
Proceeds from repurchase of equity
2,814
669
BB yield
-0.13%
-0.03%
Debt
Debt current
4,598
1,060
2,112
Long-term debt
89,669
68,030
63,354
Deferred revenue
Other long-term liabilities
2,368
2,368
2,318
Net debt
(306,260)
(91,117)
(139,167)
Cash flow
Cash from operating activities
34,599
137,948
111,658
CAPEX
(33,308)
(70,933)
(117,116)
Cash from investing activities
(75,374)
(83,704)
(153,071)
Cash from financing activities
(36,817)
(91,085)
(61,367)
FCF
40,759
9,647
(22,397)
Balance
Cash
328,302
400,943
421,729
Long term investments
72,225
(240,736)
(217,096)
Excess cash
384,626
141,780
183,237
Stockholders' equity
1,072,020
1,136,347
1,163,514
Invested Capital
1,125,171
1,363,915
1,342,378
ROIC
0.16%
3.06%
7.69%
ROCE
0.51%
3.99%
8.40%
EV
Common stock shares outstanding
86,570
86,660
86,741
Price
24.70
4.22%
23.70
-2.67%
24.35
9.19%
Market cap
2,138,279
4.11%
2,053,842
-2.76%
2,112,143
7.56%
EV
1,964,834
2,108,618
2,120,921
EBITDA
72,505
110,597
149,471
EV/EBITDA
27.10
19.07
14.19
Interest
973
755
766
Interest/NOPBT
12.60%
1.25%
0.60%